

Resource Summary Report

Generated by [dkNET](#) on Aug 25, 2026

IRAK4 Antibody

RRID:AB_2126429

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4363, RRID:AB_2126429

Antibody Information

URL: http://antibodyregistry.org/AB_2126429

Proper Citation: Cell Signaling Technology Cat# 4363, RRID:AB_2126429

Target Antigen: IRAK4

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP. Consolidation on 11/2018: AB_10695155, AB_10839262, AB_2126429.

Antibody Name: IRAK4 Antibody

Description: This polyclonal targets IRAK4

Target Organism: rat, mouse, human

Antibody ID: AB_2126429

Vendor: Cell Signaling Technology

Catalog Number: 4363

Record Creation Time: 20250820T013525+0000

Record Last Update: 20250820T112000+0000

Ratings and Alerts

No rating or validation information has been found for IRAK4 Antibody.

No alerts have been found for IRAK4 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Wu MM, et al. (2026) Macrophage PD-1 regulates energy expenditure and metabolic dysfunction under immune checkpoint blockade. *Cell metabolism*, 38(1), 208.

Sun HJ, et al. (2025) Phosphoglycerate kinase 1 contributes to diabetic kidney disease through enzyme-dependent and independent manners. *Cell reports. Medicine*, 6(8), 102241.

Campbell GR, et al. (2023) IRAK1 inhibition blocks the HIV-1 RNA mediated pro-inflammatory cytokine response from microglia. *The Journal of general virology*, 104(5).

Campbell GR, et al. (2022) Pacritinib Inhibition of IRAK1 Blocks Aberrant TLR8 Signalling by SARS-CoV-2 and HIV-1-Derived RNA. *Journal of innate immunity*, 1.

Qiu W, et al. (2021) Identification and characterization of a novel adiponectin receptor agonist adipo anti-inflammation agonist and its anti-inflammatory effects in vitro and in vivo. *British journal of pharmacology*, 178(2), 280.

Liang K, et al. (2017) Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia. *Cell*, 168(1-2), 59.